Eisai Co., Ltd. (TYO:4523)
4,601.00
-55.00 (-1.18%)
Aug 4, 2026, 10:25 AM JST
Eisai Revenue
Eisai had revenue of 234.33B JPY in the quarter ending June 30, 2026, with 15.63% growth. This brings the company's revenue in the last twelve months to 857.06B, up 6.73% year-over-year. In the fiscal year ending March 31, 2026, Eisai had annual revenue of 825.38B with 4.56% growth.
Revenue (ttm)
857.06B
Revenue Growth
+6.73%
P/S Ratio
1.59
Revenue / Employee
78.29M
Employees
10,543
Market Cap
1.31T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 825.38B | 35.98B | 4.56% |
| Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Shionogi & | 499.68B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 273.71B |
| Sawai Group Holdings | 201.68B |
| Tsumura & Co. | 192.62B |
| Nippon Shinyaku | 170.77B |
| Mochida Pharmaceutical | 116.95B |
Eisai News
- 18 hours ago - Eisai Q1 Net Income Rises - Nasdaq
- 18 hours ago - Eisai Earnings Call Transcript: Q1 2027 - Transcripts
- 18 hours ago - Eisai Quarterly report: Q1 2027 - Filings
- 18 hours ago - Eisai Slides: Q1 2027 - Filings
- 19 days ago - Biogen: LEQEMBI Real-World LEADER Study Shows Majority Of Early Alzheimer's Patients Remain Stable - Nasdaq
- 20 days ago - Eisai, Biogen Report Study Showing Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease - Nasdaq
- 20 days ago - Eisai And Biogen's SC LEQEMBI IQLIK Wins FDA Approval For Early Alzheimer's Disease - Nasdaq
- 21 days ago - FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters